PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00836875
- Locations
- πΊπΈ
Virginia Commonwealth University, Richmond, Virginia, United States
πΉπDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Patumwan, Bangkok, Thailand
πΉπDepartment of Pediatrics, Phramongkutklao hospital, Rajathevee, Bangkok, Thailand
Post Marketing Observational Study of Reformulated BeneFIX
- Conditions
- Hemophilia B
- Interventions
- Other: No intervention
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 58
- Registration Number
- NCT00835068
- Locations
- π«π·
Pfizer Investigational Site, Vandoeuvre Les Nancy Cedex, France
Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00832650
- Locations
- πΊπΈ
Pfizer Investigational Site, Rochester, Minnesota, United States
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 304
- Registration Number
- NCT00831415
- Locations
- π―π΅
Pfizer Investigational Site, Tokyo, Japan
Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2009-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT00831532
- Locations
- πΊπΈ
Pfizer Investigational Site, Indianapolis, Indiana, United States
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
- Conditions
- Alzheimer DiseaseHuntington Disease
- Interventions
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00831506
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00832052
- Locations
- πΊπΈ
Pfizer Investigational Site, Gainesville, Florida, United States
Tanezumab In Osteoarthritis Of The Knee (2)
- Conditions
- OsteoarthritisArthritis
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 832
- Registration Number
- NCT00830063
- Locations
- πΊπΈ
Valley Research, Fresno, California, United States
πΊπΈHolston Medical Group, Kingsport, Tennessee, United States
πΊπΈJeffrey D. Lieberman, MD, Decatur, Georgia, United States
Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2011-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00830050
- Locations
- π¬π§
Pfizer Investigational Site, Denmark Hill, London, United Kingdom
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
- Conditions
- Asthma, BronchialBronchial DiseasesLung Diseases, ObstructiveRespiratory Tract Diseases
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00830427